Barclays initiated coverage of Hims & Hers with an Overweight rating and $48 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- Hims & Hers announces entry into Canada
- Cautious Outlook on Hims & Hers Health Amid Acquisition Concerns and Declining Demand
- M&A News: Him & Hers Snap Up ‘Pain Free’ Blood Testing Group YourBio
- Hims & Hers to acquire YourBio Health, terms not disclosed
- Option traders moderately bearish in Hims and Hers Health with shares down 3.13%